Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06790394 | Test-retest Study With [18F]FBB in Cardiac Amyloidosis | PHASE1 | RECRUITING | 15 | — | — | Oct 21, 2025 | Sep 1, 2026 | Jun 2, 2026 | 2 | United Kingdom |
Percent Test-Retest variability (%) of cardiac 18F florbetaben PET
| Arm | Type | Description |
|---|---|---|
| Patients with cardiac disease | EXPERIMENTAL | All eligible AL, ATTR and non-CA patients will receive two injections of the investigational imaging agent florbetaben: at a baseline PET imaging session and at a follow-up PET imaging session to evaluate the test-retest imaging characteristics. 5 patients of each group will be required. |
| Name | Type | Description |
|---|---|---|
| Florbetaben F18 | DRUG | Florbetaben F18 is a radioactive diagnostic agent being developed for the indication of PET imaging of the heart to detect amyloid pathology. All patients will receive two administrations of Florbetaben F18 at a radioactive dose of 300 megabecquerel (MBq). |
Inclusion Criteria: * Inclusion criteria (for all subjects): * Males and females aged ≥40 years * Able to understand, sign, and date written informed consent * Written informed consent must be obtained before any assessment is performed * Female subjects must be documented by medical recor...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc | ALNY | 5 | PHASE3 | Vutrisiran, Sterile Normal Saline, Nucresiran, patisiran |
| Ionis Pharmaceuticals, Inc. | IONS | 4 | PHASE3 | Eplontersen |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 4 | PHASE3 | NNC6019-0001, Coramitug |
| AstraZeneca PLC | AZN | 2 | PHASE3 | Eplontersen, ALXN2220 |
| Intellia Therapeutics, Inc. | NTLA | 2 | PHASE3 | NTLA-2001 |
| Pfizer Inc. | PFE | 2 | — | Vyndamax |